These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 10623767)

  • 61. Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity.
    Joseph A; Zheng JH; Follenzi A; Dilorenzo T; Sango K; Hyman J; Chen K; Piechocka-Trocha A; Brander C; Hooijberg E; Vignali DA; Walker BD; Goldstein H
    J Virol; 2008 Mar; 82(6):3078-89. PubMed ID: 18184707
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effective Cytotoxic T Lymphocyte Targeting of Persistent HIV-1 during Antiretroviral Therapy Requires Priming of Naive CD8+ T Cells.
    Smith KN; Mailliard RB; Piazza PA; Fischer W; Korber BT; Fecek RJ; Ratner D; Gupta P; Mullins JI; Rinaldo CR
    mBio; 2016 May; 7(3):. PubMed ID: 27247230
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Recognition patterns of HLA-A2-restricted human immunodeficiency virus-1-specific cytotoxic T-lymphocytes in a cohort of HIV-1-infected individuals.
    Schmitt-Haendle M; Bachmann O; Harrer E; Schmidt B; Bäuerle M; Harrer T
    Viral Immunol; 2005; 18(4):627-36. PubMed ID: 16359229
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors.
    Betts MR; Krowka JF; Kepler TB; Davidian M; Christopherson C; Kwok S; Louie L; Eron J; Sheppard H; Frelinger JA
    AIDS Res Hum Retroviruses; 1999 Sep; 15(13):1219-28. PubMed ID: 10480635
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Characteristics of HIV-1-specific CD8 T-cell responses and their role in loss of viremia in children chronically infected with HIV-1 undergoing highly active antiretroviral therapy.
    Zhang Z; Zhao QX; Fu JL; Yao JX; He Y; Jin L; Wang FS
    Chin Med J (Engl); 2006 Dec; 119(23):1949-57. PubMed ID: 17199938
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The influence of lymphocyte counts and disease progression on circulating and inducible anti-HIV-1 cytotoxic T-cell activity in HIV-1-infected subjects.
    Grant MD; Smaill FM; Singal DP; Rosenthal KL
    AIDS; 1992 Oct; 6(10):1085-94. PubMed ID: 1361339
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Absence of Epstein-Barr virus-specific, HLA class II-restricted CD4+ cytotoxic T lymphocytes in infectious mononucleosis.
    Enssle KH; Fleischer B
    Clin Exp Immunol; 1990 Mar; 79(3):409-15. PubMed ID: 1690617
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Human immunodeficiency virus type 1 infection of antigen-specific CD4 cytotoxic T lymphocytes.
    Robbins PA; Roderiquez GL; Peden KW; Norcross MA
    AIDS Res Hum Retroviruses; 1998 Nov; 14(16):1397-406. PubMed ID: 9824317
    [TBL] [Abstract][Full Text] [Related]  

  • 69. HLA-DR and HLA-DP restricted epitopes from human cytomegalovirus glycoprotein B recognized by CD4+ T-cell clones from chronically infected individuals.
    Ventura C; Bisceglia H; Girerd-Chambaz Y; Burdin N; Chaux P
    J Clin Immunol; 2012 Dec; 32(6):1305-16. PubMed ID: 22797815
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: evidence supporting a protective role for CTL in vivo.
    Greenough TC; Brettler DB; Somasundaran M; Panicali DL; Sullivan JL
    J Infect Dis; 1997 Jul; 176(1):118-25. PubMed ID: 9207357
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Delayed virus-specific CD8+ cytotoxic T lymphocyte activity in an HIV-infected individual with high CD4+ cell counts: correlations with various parameters of disease progression.
    Dalod M; Fiorentino S; Delamare C; Rouzioux C; Sicard D; Guillet JG; Gomard E
    AIDS Res Hum Retroviruses; 1996 Apr; 12(6):497-506. PubMed ID: 8679305
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Deficient human immunodeficiency virus type 1-specific cytotoxic T cell responses in vertically infected children.
    Luzuriaga K; Koup RA; Pikora CA; Brettler DB; Sullivan JL
    J Pediatr; 1991 Aug; 119(2):230-6. PubMed ID: 1907319
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Anti-CD4 cytotoxic T lymphocyte (CTL) activity in HIV+ patients: flow cytometric analysis.
    Yamamura Y; Rodriguez N; Schwartz A; Eylar E; Yano N
    Cell Mol Biol (Noisy-le-grand); 1995; 41 Suppl 1():S133-44. PubMed ID: 8574141
    [TBL] [Abstract][Full Text] [Related]  

  • 74. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype.
    Sáez-Cirión A; Lacabaratz C; Lambotte O; Versmisse P; Urrutia A; Boufassa F; Barré-Sinoussi F; Delfraissy JF; Sinet M; Pancino G; Venet A;
    Proc Natl Acad Sci U S A; 2007 Apr; 104(16):6776-81. PubMed ID: 17428922
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Impact of antigen expression kinetics on the effectiveness of HIV-specific cytotoxic T lymphocytes.
    van Baalen CA; Guillon C; van Baalen M; Verschuren EJ; Boers PH; Osterhaus AD; Gruters RA
    Eur J Immunol; 2002 Sep; 32(9):2644-52. PubMed ID: 12207349
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Rhesus Cytomegalovirus-Specific CD8
    Rosen BC; Pedreño-Lopez N; Ricciardi MJ; Reed JS; Sacha JB; Rakasz EG; Watkins DI
    Front Immunol; 2020; 11():1960. PubMed ID: 32922404
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Differential development of CD4 and CD8 cytotoxic T cells (CTL) in PBMC across the leprosy spectrum; IL-6 with IFN-gamma or IL-2 generate CTL in multibacillary patients.
    de la Barrera S; Finiasz DM; Fink S; Valdez R; Bottasso O; Balina LM; Sasiain MC
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):45-55. PubMed ID: 9207753
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Quantitative analysis of the antiviral activity of CD8(+) T cells from human immunodeficiency virus-positive asymptomatic patients with different rates of CD4(+) T-cell decrease.
    Salerno-Gonçalves R; Lu W; Andrieu JM
    J Virol; 2000 Jul; 74(14):6648-51. PubMed ID: 10864680
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1.
    Kristoff J; Palma ML; Garcia-Bates TM; Shen C; Sluis-Cremer N; Gupta P; Rinaldo CR; Mailliard RB
    EBioMedicine; 2019 May; 43():295-306. PubMed ID: 30952614
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Induction of cytomegalovirus-specific CD4+ cytotoxic T lymphocytes from seropositive or negative healthy subjects or stem cell transplant recipients.
    Tazume K; Hagihara M; Gansuvd B; Higuchi A; Ueda Y; Hirabayashi K; Hojo M; Tanabe A; Okamoto A; Kato S; Hotta T
    Exp Hematol; 2004 Jan; 32(1):95-103. PubMed ID: 14725906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.